Q4 2020 Medivir AB Earnings Call Transcript
()-&
Thank you, operator, and warm welcome to our Q4 and full year 2020 webcast. On Slide 3, you will find our -- you will find our presentation on our home page. And on Slide 3, I do recommend everyone to read the disclaimer, which will be, as I said, on our home page as well, for those of you who are interested in the details.
Slide 5, please. This is today's outline where we will briefly touch upon our main projects and then to be rounded off with our Q4 and full year numbers.
Slide 6, please. Medivir has been around as a company since 1988 and started off as a virology-focused company back in the day. The company is listed on NASDAQ here in Stockholm. And our proprietary asset currently is MIV-818, which is a liver-directed nucleotide prodrug. We are currently in Phase Ib clinical development and aim to initiate a combination trial later this year. 818 has received Orphan Drug Designation both in EU and the U.S.
We have made a couple of achievements in the last months. We
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
